-

$undefined

N/A

(N/A)

Allakos Inc NasdaqGS:ALLK As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.

Location: 825 Industrial Road, San Carlos, CA, 94070, United States | Website: https://www.allakos.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-25.49M

Cash

55.24M

Avg Qtr Burn

N/A

Short % of Float

0.59%

Insider Ownership

1.96%

Institutional Own.

76.72%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AK006 (SC) Details Chronic spontaneous urticaria	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AK006 (IV) Details Chronic spontaneous urticaria	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Esophagitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Duodentitis , Eosinophilic Gastritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) Details Atopic dermatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) (Siglec-8) Details Chronic urticaria	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.